Skip to main content
ZURAZura Bio LimitedSell4.7·$5.85+1.74%

Zura Bio (ZURA) Q2 2026 earnings — TrendMatrix coverage

IN LINEEPS vs -$0.19 estCurrent verdict Sell 4.7/10

Reported

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure

Event detail · Q2 2026

Key numbers

Reported EPS
Estimate
-$0.19
Surprise
Score today
4.7/10

Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.

Around the report

Coverage in the report window

  • Wedbush Maintains Outperform on Zura Bio, Raises Price Target to $22benzinga, 2026-08-12
  • Guggenheim Maintains Buy on Zura Bio, Raises Price Target to $20benzinga, 2026-08-12
  • Zura Bio Q2 EPS $(0.21) Misses $(0.20) Estimatebenzinga, 2026-08-11
Current read · as of 2026-08-23

Where TrendMatrix's rating stands now

TrendMatrix currently rates ZURA Sell at 4.7/10; no pre/post engine snapshot brackets this report.

0 of the last 4 quarters beat the estimate. Next scheduled report: 2026-11-12.

What argues against it

  • Concentration risk — Pipeline: ZB Assets (tibulizumab, torudokimab, crebankitug)
  • Concentration risk — Counterparty: Pfizer and Eli Lilly license agreements
  • DATA_ISSUE: analyst_target_implausible (raw $18.00 vs price $5.85 — ratio 3.1×). Rejected, falling back to technical TP.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current engine read

The levels TrendMatrix's engine tracks

Current price
$5.85
Price target
$6.73
Stop
$5.44
Upside to target
+15.0%

Model outputs from TrendMatrix’s engine as of 2026-08-23 — shown for context, not personalized investment advice.

Healthcare context

ZURA at TrendMatrix's latest read

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry
Biotechnology
Market cap
$560.6M
P/E (fwd)
-10.0
52-week range
$1.88$7.44
Off 52-week high
21.4%
RSI (14)
59
Volume vs avg
0.95×
Score today
4.7/10

Earnings figures are sourced from TrendMatrix’s pipeline (EPS: existing earnings extraction; revenue: SEC XBRL company facts where available, yfinance-provisional otherwise). Not a buy/sell rating, a price target, or investment advice — see the current verdict on the stock’s main page for TrendMatrix’s live read.

Home Stocks ZURA Earnings Q2 2026 earnings